Poly(L-glutamic acid)--anticancer drug conjugates

Adv Drug Deliv Rev. 2002 Sep 13;54(5):695-713. doi: 10.1016/s0169-409x(02)00045-5.

Abstract

Chemotherapy has had limited success in the treatment of cancer over the years, due, in part, to the untoward toxicity of the therapeutic agent to normal cells. The design of tailor-made polymer conjugates provides a synthetic approach that can overcome some of the problems. Several synthetic polymer-based anticancer drug conjugates have entered clinical studies. This report reviews the chemistry, physicochemical properties, and therapeutic applications in cancer therapy of polymeric chemotherapeutic agents based on poly(L-glutamic acid). Targeted delivery of anticancer agents using poly(L-glutamic acid) as the drug carrier is also discussed with emphasis on the design of innovative polymeric constructs.

Publication types

  • Review

MeSH terms

  • Anthracyclines / administration & dosage
  • Anthracyclines / therapeutic use
  • Antimetabolites / administration & dosage
  • Antimetabolites / therapeutic use
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use
  • Camptothecin / administration & dosage
  • Camptothecin / therapeutic use
  • Clinical Trials as Topic
  • DNA / metabolism
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Neoplasms / drug therapy
  • Paclitaxel / administration & dosage
  • Paclitaxel / therapeutic use
  • Polyglutamic Acid* / chemical synthesis
  • Polyglutamic Acid* / pharmacokinetics

Substances

  • Anthracyclines
  • Antimetabolites
  • Antineoplastic Agents
  • Drug Carriers
  • Polyglutamic Acid
  • DNA
  • Paclitaxel
  • Camptothecin